R&D The Chairman & CEO of SV More speaks about the path that led him to found the company nearly three decades ago, what changes need to be made in the future in order to maintain the current success of the company, and what aspect of his company makes him the…
R&D Francis del Val, President & Managing Director of GSK, Philippines, talks about his experience working in the pharmaceutical and healthcare sector in the Philippines, and discusses at length the company’s (and industry’s) largest challenge: Employee retention. The growth of the pharmaceutical market, according to IMS Health data, is only set…
R&D John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still, and his strategy for the company’s international exposure. How did you come to lead HTX and what are the parallels…
R&D Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a wider variety of areas within the industry. What opportunity did you see in moving your career from Pharmascience to Pharmetics? The business opportunity was…
R&D Patrick Tête, Managaing Director of Servier Philippines, speaks about the differences between running the company in Australia and in the Philippines, that the office and company culture is very similar, however, working in a healthcare system exposed to such severe corruption clearly makes the job more complicated in the Philippines.…
R&D António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the US, as well as the unique long-term strategy of the company and the advantages to being a family-run business. Last…
R&D Ramón Palou de Comasema, Country Director of Amgen Portugal, talks about the struggle to enter the reimbursement process in Portugal, how Amgen Portugal has broken this trend by having three of its products reimbursed in the last four years, and further highlights the affiliate’s successes and future growth outlook. How…
R&D Nuno Brás, General Manager of LEO Farmacêuticos discusses the effect of the crisis on the Portuguese pharmaceutical market, how being a small privately owned company was an advantage during the crisis, and what future growth looks like for the company as well as the industry. You have had the opportunity…
partnering David Setboun, Country President of AstraZeneca, discusses the opportunities that the Portuguese market can bring despite economic downturn, and the future of the Portuguese affiliate in expanding to new therapeutic areas. In what way do you think the pharmaceutical industry can act as an engine of economic recovery and development…
R&D Angelini Portugal’s Luigi Cianci offers his critique of the decline of Portugal’s economy and its effects on the industry, talking specifically about the company’s presence in Portugal and its export market—Angelini is one of a few multinationals that produces in conjunction with local facilities. What is your perception of the…
R&D Nelson Ambrogio, managing director of Bayer Portugal, talks about tthe collaboration between the industry and the government, he recent successes of his affiliate, and strategies for continued growth during the toughest years of the crisis in Portgugal. Why did you choose to come to Portugal during such a challenging time…
See our Cookie Privacy Policy Here
